Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

In Vivo panCAR-Mediated Depletion of B Cells in Non-Human Primates Using a Circular (oRNA®) Anti-CD20 CAR

Blood (2024) 144 (Supplement 1): 3427.

https://doi.org/10.1182/blood-2024-210256

Published: 2024

Journal Articles

CD20-bispecific antibodies improve response to CD19-CAR T cells in lymphoma in vitro and CLL in vivo models

Berit J. Brinkmann, Alessia Floerchinger, Christina Schniederjohann, Tobias Roider, Mariana Coelho, Norman Mack, Peter-Martin Bruch, Nora Liebers, Sarah Dötsch, Dirk H. Busch, Michael Schmitt, Frank Neumann, Philipp M. Roessner, Martina Seiffert, Sascha Dietrich

Blood (2024) 144 (7): 784–789.

https://doi.org/10.1182/blood.2023022682

Published: 2024

Includes: Supplemental data

Journal Articles

Statistical Challenges from Trials of Potentially Curative Treatments: Validation of Cure Assumptions When Analyzing Zuma-7 Follow-up Data of Axi-Cel and Standard of Care Therapy

Anik R Patel, Mark Ray, Yael A Rodriguez-Guadarrama, Nathaniel J Smith, Frank Neumann, Rob Blisset, Allen Xiaodong Xue

Blood (2023) 142 (Supplement 1): 6899.

https://doi.org/10.1182/blood-2023-181255

Published: 2023

Journal Articles

Monocyte Subpopulations and Their Expression of HLA-DR and CD300e after Allogeneic Stem Cell Transplantation in Patients with or without GvHD

Igor Age Kos, Jörg-Thomas Bittenbring, Onur Cetin, Vadim Lesan, Konstantinos Christofyllakis, Frank Neumann, Lorenz Thurner, Moritz Bewarder

Blood (2023) 142 (Supplement 1): 7010.

https://doi.org/10.1182/blood-2023-185530

Published: 2023

Journal Articles

Hyper N-Glycosylated SEL1L3 As B-Cell Receptor Autoantigen of Primary Vitreoretinal Lymphoma

Moritz Bewarder, Michelle Elbert, Konstantinos Christofyllakis, Kristina Heyne, Gabi Carbon, Natalie Fadle, Evi Regitz, Maximilian Kiefer, Igor Age Kos, Joerg Thomas Bittenbring, Frank Neumann, Falko Fend, Irina Bonzheim, Lorenz Thurner

Blood (2022) 140 (Supplement 1): 3042–3043.

https://doi.org/10.1182/blood-2022-170027

Published: 2022

Journal Articles

Major Adverse Cardiac, Arterial Occlusive, and Venous Occlusive Events Among Chronic Myeloid Leukemia Patients Prescribed Ponatinib Vs Bosutinib

Moshe Yair Levy, MD, Lin Xie, MA, MS, Yuexi Wang, Frank Neumann, MD PhD, Shouryadeep Srivastava, MBBS, PhD, Daniel Naranjo, Jing Xu, Qisu Zhang, MPH, Mehul Dalal, PhD

Blood (2019) 134 (Supplement_1): 4751.

https://doi.org/10.1182/blood-2019-129053

Published: 2019

Journal Articles

The B-Cell Receptor Antigen ARS2 Can be Integrated into a BAR-Body Format to Treat Diffuse Large B-Cell Lymphomas in Xenograft Mouse Models

Moritz Bewarder, MD, Christina Körbel, PhD, Matthias W. Laschke, PhD, Michael D. Menger, MD, Maximilian Kiefer, Dominic Kaddu-Mulindwa, MD, Helene Will, Lisa Goerens, Natalie Fadle, Evi Regitz, Stephan Stilgenbauer, Frank Neumann, PhD, Klaus Dieter Preuss, PhD, Michael Pfreundschuh, MD, Lorenz Thurner, MD

Blood (2019) 134 (Supplement_1): 2860.

https://doi.org/10.1182/blood-2019-131434

Published: 2019

Journal Articles

β 2 -m - a Trigger for NLRP3 Inflammasome Activation within Macrophages Promoting Multiple Myeloma Cell Proliferation

Daniel Hofbauer, Dimitrios Mougiakakos, MD, Maike Büttner-Herold, Frank Neumann, PhD, Jens Nolting, Savita Bisht, Robert Zeiser, MD, Shaima'A Hamarsheh, MSc,BSc, Stefano Ricagno, PhD, Mario Zaiss, Martin Eberhardt, Martin Boettcher, PhD, Katrin Bitterer, Andreas Mackensen, MD, Heiko Bruns, PhD

Blood (2019) 134 (Supplement_1): 2314.

https://doi.org/10.1182/blood-2019-123958

Published: 2019

Journal Articles

Identification and Characterization of CMV-Specific, HLA-C*07:02 Restricted Antibodies

Moritz Bewarder, MD, Gerhard Held, MD, Lorenz Thurner, MD, Klaus Dieter Preuss, PhD, Gabi Carbon, Birgit Bette, Konstantinos Christofyllakis, MD, Arne Felbel, Dominic Kaddu-Mulindwa, MD, Niels Murawski, MD, Stephan Stilgenbauer, Frank Neumann, PhD

Blood (2019) 134 (Supplement_1): 5616.

https://doi.org/10.1182/blood-2019-126998

Published: 2019

Journal Articles

Real-World Comparisons of Cardiovascular Events between Different Tyrosine Kinase Inhibitors Among Patients with Chronic Myeloid Leukemia

Moshe Yair Levy, MD, Lin Xie, MA, MS, Yuexi Wang, Frank Neumann, MD PhD, Shouryadeep Srivastava, MBBS, PhD, Daniel Naranjo, Qisu Zhang, Mehul Dalal, PhD

Blood (2018) 132 (Supplement 1): 3567.

https://doi.org/10.1182/blood-2018-99-113490

Published: 2018

Journal Articles

BAR-Bodies: B-Cell Receptor Antigens As the Targeting Moiety of Antibodies in Substitution for the Variable Region of Heavy and Light Chains

Moritz Bewarder, MD, Lorenz Thurner, MD, Frank Neumann, PhD, Natalie Fadle, Evi Regitz, Maria Kemele, Helene Will, Lisa Goerens, Konstantinos Christofyllakis, MD, Dominic Kaddu-Mulindwa, MD, Stephan Stilgenbauer, Maximilian Kiefer, Klaus Dieter Preuss, PhD

Blood (2018) 132 (Supplement 1): 2940.

https://doi.org/10.1182/blood-2018-99-115348

Published: 2018

Journal Articles

Gene Set Enrichment Analysis Suggests That Increased Rituximab-Mediated NK Cell Cytotoxicity after Vitamin D Substitution Is Driven By Upregulation of Interferon Alpha (IFN-a) Isoforms

Konstantinos Christofyllakis, MD, Frank Neumann, PhD, Stephan Stilgenbauer, Dominic Kaddu-Mulindwa, MD, Evi Regitz, Moritz Bewarder, MD, Andreas Keller, PhD MSc, Jörg Thomas Bittenbring, MD

Blood (2018) 132 (Supplement 1): 3696.

https://doi.org/10.1182/blood-2018-99-111817

Published: 2018

Journal Articles

Arterial Occlusive Events (AOEs) in the Phase 2 Ponatinib PACE Trial: 5-Year Update in Heavily Treated Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

Blood (2017) 130 (Supplement 1): 2896.

https://doi.org/10.1182/blood.V130.Suppl_1.2896.2896

Published: 2017

Journal Articles

Efficacy and Safety of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) According to the Extent of Treatment with Prior Tyrosine Kinase Inhibitors (TKIs): Final (5-Year) Results of the PACE Study

Blood (2017) 130 (Supplement 1): 1617.

https://doi.org/10.1182/blood.V130.Suppl_1.1617.1617

Published: 2017

Journal Articles

Altered Expression of Neddylation Pathway Proteins in Myelodysplastic Syndromes

Fatemeh Majidi, MD, Judith Neukirchen, MD, Simon Brille, Iris Fey, BSc., Frank Neumann, MDPhD, Allison Berger, PhD, Ron-Patrick Cadeddu, PhD, Martina Rudelius, MD, Ulrich Germing, MD, Rainer Haas, MD, Norbert Gattermann, MD

Blood (2017) 130 (Supplement 1): 5298.

https://doi.org/10.1182/blood.V130.Suppl_1.5298.5298

Published: 2017

Journal Articles

BARs ( B -cell receptor a ntigens for r everse targeting): A Novel and Ultimately Specific Treatment Concept for B-Cell Neoplasms

Michael Pfreundschuh, MD, Lorenz Thurner, MD, Stefan Barth, Prof.Dr., Diana Pickert, Natalie Fadle, Maria Kemele, Evi Regitz, Frank Neumann, PhD, Thomas Nachreiner, Dr., Klaus-Dieter Preuss, PhD

Blood (2015) 126 (23): 3995.

https://doi.org/10.1182/blood.V126.23.3995.3995

Published: 2015

Journal Articles

Lenalidomide Enhances MOR202 Dependent Macrophage-Mediated Effector Functions Via the Vitamin D Pathway

Heiko Bruns, PhD, Regina Jitschin, PhDMD, Dimitrios Mougiakakos, Joerg Thomas Bittenbring, MD, Jens Nolting, Maike Büttner, Michael Rehli, PhD, Julia Wimmer, Frank Neumann, PhD, Christian Bach, Heidi Balzer, Stephanie Moi, Peter Brossart, MD, Armin Gerbitz, MD, Andreas Mackensen, MD

Blood (2015) 126 (23): 2203.

https://doi.org/10.1182/blood.V126.23.2203.2203

Published: 2015

Journal Articles

Peripheral B Cells from Patients with MGUS and Multiple Myeloma (MM) Can Be Stimulated by Paraprotein-Target Specific T-Helper Cells to Produce Paraprotein-Identical Monoclonal Antibodies: Rationale for PARs, a Novel Therapeutic Approach with Ultimate Specificity in MGUS/MM

Frank Neumann, PhD, Boris Kubuschok, MD, Klaus-Dieter Preuss, PhD, Claudia Schormann, Michael Pfreundschuh, MD

Blood (2015) 126 (23): 1817.

https://doi.org/10.1182/blood.V126.23.1817.1817

Published: 2015

Journal Articles

Optimizing 25-OH-Vitamin D3 Serum Levels for Rituximab- and Obinutuzumab-Mediated Antibody-Dependent Cellular Cytotoxicity

Joerg Thomas Bittenbring, MD, Michael Pfreundschuh, MD, Fabian Acker, Frank Neumann, PhD

Blood (2015) 126 (23): 2734.

https://doi.org/10.1182/blood.V126.23.2734.2734

Published: 2015

Journal Articles

Preclinical and Clinical Pharmacodynamics of Pan-Pim Inhibition By AZD1208 in Acute Myeloid Leukemia: Assessment of Pim Isoform Dependency for Bad and 4EBP1 Phosphorylation

Kristen A McEachern, PhD, Adriana E Tron, PhD, Greg O'Connor, Rachel DuPont, Francis D Gibbons, PhD, Lourdes Pablo, Karthick Vishwanathan, PhD, Patricia McCoon, PhD, Jorge E. Cortes, MD, Daniel J. DeAngelo, MDPhD, Mark D Minden, MDPhD, Geoffrey L. Uy, MD, Frank Neumann, MDPhD, Karen Keating, Dennis Huszar, PhD, J. Elizabeth Pease, PhD, Jeffrey Brown, PhD, J. Carl Barrett, PhD

Blood (2014) 124 (21): 906.

https://doi.org/10.1182/blood.V124.21.906.906

Published: 2014

NARROW

In Vivo panCAR-Mediated Depletion of B Cells in Non-Human Primates Using a Circular (oRNA®) Anti-CD20 CAR

CD20-bispecific antibodies improve response to CD19-CAR T cells in lymphoma in vitro and CLL in vivo models

Statistical Challenges from Trials of Potentially Curative Treatments: Validation of Cure Assumptions When Analyzing Zuma-7 Follow-up Data of Axi-Cel and Standard of Care Therapy

Monocyte Subpopulations and Their Expression of HLA-DR and CD300e after Allogeneic Stem Cell Transplantation in Patients with or without GvHD

Hyper N-Glycosylated SEL1L3 As B-Cell Receptor Autoantigen of Primary Vitreoretinal Lymphoma

Major Adverse Cardiac, Arterial Occlusive, and Venous Occlusive Events Among Chronic Myeloid Leukemia Patients Prescribed Ponatinib Vs Bosutinib

The B-Cell Receptor Antigen ARS2 Can be Integrated into a BAR-Body Format to Treat Diffuse Large B-Cell Lymphomas in Xenograft Mouse Models

β 2 -m - a Trigger for NLRP3 Inflammasome Activation within Macrophages Promoting Multiple Myeloma Cell Proliferation

Identification and Characterization of CMV-Specific, HLA-C*07:02 Restricted Antibodies

Real-World Comparisons of Cardiovascular Events between Different Tyrosine Kinase Inhibitors Among Patients with Chronic Myeloid Leukemia

BAR-Bodies: B-Cell Receptor Antigens As the Targeting Moiety of Antibodies in Substitution for the Variable Region of Heavy and Light Chains

Gene Set Enrichment Analysis Suggests That Increased Rituximab-Mediated NK Cell Cytotoxicity after Vitamin D Substitution Is Driven By Upregulation of Interferon Alpha (IFN-a) Isoforms

Arterial Occlusive Events (AOEs) in the Phase 2 Ponatinib PACE Trial: 5-Year Update in Heavily Treated Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

Efficacy and Safety of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) According to the Extent of Treatment with Prior Tyrosine Kinase Inhibitors (TKIs): Final (5-Year) Results of the PACE Study

Altered Expression of Neddylation Pathway Proteins in Myelodysplastic Syndromes

BARs ( B -cell receptor a ntigens for r everse targeting): A Novel and Ultimately Specific Treatment Concept for B-Cell Neoplasms

Lenalidomide Enhances MOR202 Dependent Macrophage-Mediated Effector Functions Via the Vitamin D Pathway

Peripheral B Cells from Patients with MGUS and Multiple Myeloma (MM) Can Be Stimulated by Paraprotein-Target Specific T-Helper Cells to Produce Paraprotein-Identical Monoclonal Antibodies: Rationale for PARs, a Novel Therapeutic Approach with Ultimate Specificity in MGUS/MM

Optimizing 25-OH-Vitamin D3 Serum Levels for Rituximab- and Obinutuzumab-Mediated Antibody-Dependent Cellular Cytotoxicity

Preclinical and Clinical Pharmacodynamics of Pan-Pim Inhibition By AZD1208 in Acute Myeloid Leukemia: Assessment of Pim Isoform Dependency for Bad and 4EBP1 Phosphorylation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only